Barinthus Biotherapeutics plc American Depositary Shares (BRNS) is a publicly traded Healthcare sector company. As of May 21, 2026, BRNS trades at $0.69 with a market cap of $26.08M and a P/E ratio of -0.42. BRNS moved +2.41% today. Year to date, BRNS is -5.52%; over the trailing twelve months it is -22.81%. Its 52-week range spans $0.51 to $2.92. Analyst consensus is buy with an average price target of $7.00. Rallies surfaces BRNS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own BRNS include Bluecrest Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Barinthus Biotherapeutics plc American Depositary Shares.
| Metric | Value |
|---|---|
| Price | $0.69 |
| Market Cap | $26.08M |
| P/E Ratio | -0.42 |
| EPS | $-1.64 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.92 |
| 52-Week Low | $0.51 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $506.00K |
| Net Income | $-66.46M |
| Gross Margin | 0.00% |
1 analysts cover BRNS: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.00.